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ABSTRACT 22 
The extracellular domain of influenza A virus matrix protein 2 (M2, M2e) is conserved 23 
and is being evaluated as a quasi-universal influenza A vaccine candidate. We describe 24 
the crystal structure at 1.6 Å resolution of M2e in complex with the Fab fragment of an 25 
M2e-specific monoclonal antibody that protects against influenza A virus challenge. 26 
This antibody binds M2 expressed on the surface of cells infected with influenza A 27 
virus. Five out of six complementary determining regions interact with M2e, and three 28 
highly conserved M2e residues are critical for this interaction. In this complex, M2e 29 
adopts a compact U-shaped conformation stabilized in the centre by the highly 30 
conserved tryptophan residue in M2e. This is the first description of the three 31 
dimensional structure of M2e. 32 
 33 
 34 
IMPORTANCE 35 
M2e of influenza A is under investigation as a universal influenza A vaccine, but its 36 
three dimensional structure is unknown. We describe the structure of M2e stabilized 37 
with an M2e-specific monoclonal antibody that recognizes natural M2. We found that 38 
the conserved tryptophan is positioned in the centre of the U-shaped structure of M2e 39 
and stabilizes its conformation. The structure also explains why previously reported in 40 
vivo escape viruses, selected with a similar monoclonal antibody, carried proline 41 
residue substitutions at position 10 in M2.       42 
 3 
 
INTRODUCTION 43 
Matrix protein 2 (M2) is a structural protein of influenza A viruses and plays an important 44 
role in the virus life cycle. This long type III membrane protein of 96 amino acid residues 45 
has an N-terminal ectodomain (M2e) of 23 residues, a transmembrane domain of 19 residues, 46 
and a cytoplasmic domain of 54 residues (1). M2 is classified as a viroporin. Mutational 47 
analysis and crystal and NMR structural analysis of the M2 transmembrane domain revealed 48 
that it is composed of a four-stranded coiled coil and that two conserved amino acid residues 49 
(M2-His37 and -Trp41) have a key role in acid-induced proton gating (2-5). Following 50 
endocytosis of influenza A virions, the acidic endosomal environment activates the M2-51 
channel so that protons enter the virion interior. The resulting acidification loosens the viral 52 
ribonucleoprotein complexes from matrix protein 1 (M1), which facilitates their migration 53 
through the membrane fusion pore into the host cell cytoplasm (6, 7). M2 can activate the 54 
inflammasome, impairs autophagosome maturation and was recently shown to recruit parts 55 
of the autophagosome machinery to sites of virus budding by a conserved motif in its 56 
cytoplasmic domain (8, 9).  57 
The sequence of M2e is conserved and therefore has frequently been explored for the 58 
development of a universal influenza A vaccine (10-13). Immune protection by M2e-59 
directed vaccines has been documented extensively in experimental animal models, 60 
including mice, ferrets and swine (11-13). In addition, a phase I clinical study showed that 61 
M2e-based vaccines are safe and immunogenic in human (10, 14). Seasonal influenza A 62 
virus infection induces a poor immune responses to M2e, but this weak response against 63 
M2e in humans was boosted following infection with 2009 pandemic H1N1 influenza virus 64 
(15). Protection induced by M2e-based vaccines such as M2e displayed on recombinant 65 
virus-like particles is mediated by antibodies (11) and, like the in vitro broadly neutralizing 66 
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HA stalk-specific antibodies (16), depends on activating Fcγ receptors (11, 16, 17). In line 67 
with this, passive transfer of mouse and human monoclonal antibodies directed against M2e 68 
can protect against influenza A virus challenge (11, 18-21). It has also been reported that 69 
treatment of experimentally challenged human volunteers with a human monoclonal 70 
antibody directed against M2e reduces viral replication and clinical symptoms (Ramos, E., 71 
Options for the Control of Influenza VIII, September 9, 2013)(22). 72 
Crystal structures of the extracellular domain of influenza hemagglutinin (HA) and 73 
neuraminidase (NA), either as a free form or as a complex with an Fab or with single chain 74 
Fv fragments of monoclonal antibodies, have been described (23). Atomic resolution 75 
structures of the M2 transmembrane domain and of part of the cytosolic domain of M2 have 76 
also been reported (5). The transmembrane domain forms a four-helix bundle with a helical 77 
tilt of approximately 30? relative to the central axis of the bundle. The membrane proximal 78 
cytosolic part of M2 forms an amphipathic α helix almost perpendicular to the membrane 79 
spanning α helix of M2 (24, 25). However, the three dimensional structure of M2e has 80 
remained unknown. Here, we report a high resolution crystal structure of M2e in complex 81 
with the Fab of a protective M2e-specific monoclonal antibody (mAb). In this complex, M2e 82 
adopts a U-shape with M2-Trp15 positioned in the center. The structure reveals a critical 83 
role for M2-Glu6, -Pro10, -Ile11, and -Trp15 in monoclonal antibody binding. This 84 
observation explains why previously reported escape viruses, isolated from infected SCID 85 
mice treated with a similar M2e-specific mAb, encoded M2 with a Pro10-to-Leu or Pro10-86 
to-His mutation (26). 87 
88 
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MATERIALS AND METHODS 89 
Digestion and purification of mAb 65 Fab fragments. Monoclonal antibody 65 (mAb65) 90 
is a mouse IgG2a antibody isolated using conventional hybridoma technology and 91 
splenocytes from BALB/c mice immunized with M2e-tGCN4 (27). MAb-65 (3 mg) was 92 
treated with papain at a ratio of 1:50 (w/w) for 3 h in PBS buffer with 5 mM L-cysteine and 93 
5 mM EDTA at 37ºC. Proteolysis was halted by adding crystalline iodoacetamide to a final 94 
concentration of 30 mM. The mixture was then dialyzed against PBS buffer, and the mAb65 95 
antigen-binding fragments (Fab65) was separated from the Fc fragment on a Protein A 96 
column. The unbound fraction was further purified by Superdex 200 HR size-exclusion 97 
chromatography.  98 
Protein crystallization and data collection. An HPLC-purified synthetic M2e peptide 99 
(MSLLTEVETPIRNEWGCRCNDSS, Anygen, Jeollanam-do, Korea) was mixed with 100 
purified Fab65 at a 5:1 molar ratio in 20 mM Tris-HCl (pH8.0) and 50 mM NaCl buffer. 101 
After 12 h at 4°C, the mixture was loaded two successive times on a Superdex 75 HR 102 
column to purify M2e–Fab65 complexes. The complex of M2e peptide with Fab65 in 20 103 
mM Tris-HCl (pH8.0), 50 mM NaCl, and 5 mM DTT was screened for crystal formation by 104 
a vapor diffusion method using commercial screening kits and an Oryx4 crystallization robot 105 
(Douglas Instruments Ltd., Berkshire, UK). Thin rhombic crystals of M2e–Fab65 complex 106 
were obtained in 20% PEG 3350 and 200 mM NaCl in one week. Diffraction data at 1.6 Å 107 
resolution of the M2e–Fab65 complex were collected at 100K in a stream of liquid N2 using 108 
synchrotron sources at beamline BL-17A in the Photon Factory (Tsukuba, Japan). For the 109 
M2e–Fab65 complex, the space group is P1. All data were processed and scaled using the 110 
HKL2000 program (28).  111 
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Structure solution and refinement. The heavy chain structure in the M2e?Fab65 complex 112 
was solved by molecular replacement (MR) using the heavy chain of Fab CR6261 (PDB ID: 113 
3GBM) as template, and the light chain structure of Fab65 was solved using the light chain 114 
of Fab CR6261 after fixing the MR solution of the heavy chain of Fab65. MR was 115 
performed by Molrep in CCP4 Suit (29). The initial solution was optimized by rigid body 116 
refinement, and correct sequences of Fab65 were applied. Manual adjustment of M2e 117 
peptide and Fab65 was conducted in Coot (30) based on difference Fourier maps (2|Fo|-|Fc| 118 
and |Fo|-|Fc|) and refinements were carried out using Refmac5 (29). After a few rounds of 119 
model rebuilding, water molecules were added at the |Fo|-|Fc| map peaks above 3.0?. Data 120 
and refinement statistics are summarized in Table 1. Prediction of free energy differences of 121 
the M2e–Fab65 interface was performed by YASARA at pH7 and 298K (31). The shape 122 
complementarity score was calculated using SC in CCP4 Suite. All structural images were 123 
created using PyMol (Delano Scientific, http://www.pymol.org). 124 
Biochemical characterization. For peptide ELISA, wild type M2e 125 
(SLLTEVETPIRNEWGCRCNDSSDSG), M2eP10L 126 
(SLLTEVETLIRNEWGCRCNDSSDSG), or M2eW15G 127 
(SLLTEVETPIRNEGGCRCNDSSDSG) were coated on a 96-well Maxisorp plate at 37ºC 128 
overnight, followed by blocking with 3% skim milk in PBS buffer. The plate was then 129 
incubated with mAb65 or mAb148 (a mouse monoclonal IgG1 antibody that recognizes the 130 
first 9 amino acids of M2e) as primary antibodies. After vigorous washing with 0.1% Tween 131 
20 in PBS buffer, binding was detected using HRP-conjugated anti-mouse Abs. For cell-132 
based ELISA, pDWPI-M2-Flag plasmids with the respective alanine mutation were 133 
transfected into HEK293T cells using calcium phosphate precipitation. After 24 h, cells were 134 
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fixed with 4% paraformaldehyde, and M2e expressed on the cell surface was detected in the 135 
same way as the peptide ELISA described above.  136 
For Fourier transform infrared spectroscopy (FTIR), the M2e peptide was dissolved in PBS 137 
buffer at 2?4 mg/ml, and FTIR spectra were recorded on a Tensor 27 FT-IR (Bruker Optics 138 
GmbH, Ettlingen, Germany) using a Bio-ATRCell II (Harrick Scientific Products Inc., 139 
Pleasantville, NY 10570, USA) at 25ºC. The data shown in Fig. 5C are the average of 256 140 
spectra at a resolution of 2 nm. 141 
For alanine-scanning, pDWPI-M2-Flag plasmids with the respective alanine mutation were 142 
transfected into HEK293T cells using calcium phosphate precipitation. After 48 h, the cells 143 
were lysed in 50 mM Tris-HCl (pH8.0), 150 mM NaCl, 1% NP40, 5 mM EDTA, and 144 
proteinase inhibitor cocktail. The lysate was analyzed by western blot using mAb65, mAb 145 
14C2 (Enzo Life Sciences) and anti-Flag antibody (Sigma-Aldrich) as primary antibodies 146 
and HRP-conjugated anti-mouse antibody as secondary antibody. 147 
Influenza A virus plaque reduction assay. PR8, WSN, A/USSR/77 and X31 (H3N2) 148 
viruses were produced in MDCK cells. An amount of virus corresponding to a 149 
predetermined titer of 5~10 PFU/well (of a 96 well microtiter plate) was mixed with 10 fold 150 
serial dilution of mAb65 (starting concentration of 10 μg/ml), mAb3G8 (an IgG2a 151 
monoclonal antibody specific for Respiratory Syncytial virus small hydrophobic protein), 152 
amantadine (starting concentration 100 μM, Sigma) or polyclonal goat anti-PR8 immune 153 
serum (NIH Biodefense and Emerging Infections Research Resources Repository NR-3148). 154 
After one h incubation at RT, the mixture was transferred to monolayers of MDCK cells 155 
seeded in 96-well plates and the plates were incubated at 37ºC. After 1 h, the medium was 156 
removed and 0.6% Avicel in serum-free medium containing 1 μg/ml trypsin and antibodies 157 
or amantadine was applied as an overlay. Twenty h later, the overlay was removed, cells 158 
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were fixed with 4% paraformaldehyde and the plaques were stained with goat anti-RNP 159 
antibody (NIH Biodefense and Emerging Infections Research Resources Repository NR-160 
3133), followed by incubation with HRP-labelled donkey anti-goat Ig serum (Santa Cruz 161 
Biotechnology Inc., TX, USA) and finally revealed by staining with True-Blue peroxidase 162 
substrate (Kirkegaard & Perry Laboratories, Inc, Gaithersburg, MD, USA). 163 
Immunofluorescence microscopy. MDCK cells were seeded at 30,000 cells on glass cover 164 
slips in 24-well plates. After 24 h, cells were infected with PR8, pandemic H1N1 2009, 165 
Mallard Duck/ALB/1979 (H3N6), Chicken/Nanchang/2001 (H3N2) or Swine/Ontario/2001 166 
(H3N3) (MOI = 0.5), or were mock infected. After 24 h, the cells were fixed with 2% 167 
paraformaldehyde in PBS for 30 min on ice. The cells were stained with anti-NP antibody 168 
(obtained from BEI Resources, NIAID, NIH: Polyclonal Anti-Influenza Virus RNP, 169 
A/Scotland/840/1974 (H3N2), goat antiserum), and mAb148 or mAb65. Images were 170 
recorded with a confocal microscope (Leica Sp5 AOBS confocal system). 171 
Reverse genetic virus production. Site-directed mutagenesis of M2e in pHW197-M (32) 172 
was performed by polymerase chain reaction (PCR) using primers incorporating the desired 173 
mutant sequences. Influenza A virus rescue from the PR/8 plasmid system was performed on 174 
a HEK293T-MDCK co-culture as previously described (32). To analyze the expression of 175 
M1 and M2, the pHW197-M wild type and mutant plasmids were transfected into HEK293T 176 
cells together with pCAXL-PA, pCAXL-PB1, pCAXL-PB2, and pCAXL-NP (33) in 12-well 177 
plates. After 48 h, expression was analyzed by western blot using polyclonal goat anti-178 
influenza virus RNP (NIH Biodefense and Emerging Infections Research Resources 179 
Repository NR-3133), mAb148, mAb65 and goat anti-M1 antibody as primary antibodies. 180 
To generate reverse genetic viruses, pHW193-PA, pHW192-PB1, pHW191-PB2, pHW195-181 
NP, pHW198-NS1, pHW196-NA, pHW194-HA, and mutated pHW197-M were co-182 
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transfected into HEK293T cells and MDCK co-cultures in 6-well plates. After 24 h, 2 μg/ml 183 
of trypsin was added to the media, and virus production was assessed by determining 184 
hemagglutination activity and plaque forming units in the supernatant. For plaque assay, 185 
MDCK cells in a 24-well plate were incubated with virus in serum free-medium at 37ºC. 186 
After 1 h, the medium was removed and 0.6% of Avicel in serum-free media containing 2 187 
μg/ml trypsin was used as an overlay. After 2 days at 37ºC, plaques were stained with goat 188 
anti-RNP antibody, followed by detection with True-Blue peroxidase substrate (Kirkegaard 189 
& Perry Laboratories, Inc, Gaithersburg, MD, USA). 190 
Protein structure accession number. The M2e peptide and Fab65 complex structure has 191 
been deposited in the Protein Data Bank (PDB) under the PDB code 4N8C. 192 
  193 
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RESULTS 194 
Structure of M2e in complex with monoclonal antibody 65. We isolated a monoclonal 195 
antibody (mAb65, IgG2a) from BALB/c mice that had been immunized with a soluble 196 
tetrameric form of M2e (M2e-tGCN4) (27). Passive transfer of mAb65 protected laboratory 197 
mice against influenza A virus challenge (34). First, we crystallized M2e-tGCN4 but were 198 
unable to accurately model the M2e part because its electron density map was too weak (data 199 
not shown). We then crystallized an M2e-peptide comprising amino acids 1?23 complexed 200 
with Fab65. The crystals diffracted X-rays to 1.6 Å resolution and allowed us to model the 201 
heavy chain (H) from residues 1 to 221, the light chain (L) from residues 1 to 220 of mAb65, 202 
and M2e from residues 2 to 16 (Fig. 1A). This structure showed that all three heavy chain 203 
CDRs (HCDRs) and light chain CDRs (LCDRs) 1 and 3 contact M2e (Fig. 1B). The total 204 
surface area of the peptide that is buried by the Fab is 747.9 Å2 and that of the Fab buried by 205 
M2e is 655.6 Å2, which are larger than those reported for the complex between motavizumab 206 
and a human respiratory syncytial virus F-derived peptide (35). The shape complementarity 207 
score of the M2e–Fab65 interface is high (0.77 for HCDRs and 0.90 for LCDRs), exceeding 208 
that of HA stem-Fab complexes (Fig. 1C). 209 
The interactions between M2e and Fab65 CDRs are mainly through His35, Asn55, Asn59 210 
and Arg99 of the HCDRs, and the hydroxyl groups of Tyr31, Tyr98 and Tyr100 in the 211 
LCDRs. M2-Glu6 is a key interacting residue. Its side chain carboxyl group forms a salt 212 
bridge with the side chains of His35 (HCDR1) and Arg99 (HCDR3) as well as a hydrogen 213 
bond with the main chain nitrogen of Ala33 in HCDR1 (Fig. 2A). M2-Glu6 also interacts 214 
with the main chain oxygen of Ala33 and the main chain nitrogen of Arg99 in HCDR3 215 
through a water molecule (Fig. 2A). The main chain oxygen of M2-Glu6 also forms a 216 
hydrogen bond with the hydroxyl group of Tyr100 of LCDR3. Moreover, M2-Glu6 is 217 
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associated with residues Thr30, Tyr32, Ala33, Thr53 and Asp54 in the HCDRs via water-218 
mediated hydrogen-bond networks (Fig. 2B). It is known that water molecules can form an 219 
intricate network that makes antibody-antigen interfaces fully complementary (36, 37). 220 
Additionally, the side chain of M2-Glu8 interacts with those of Asn55 and Asn57 of the 221 
HCDR2 through water molecules, and its main chain oxygen interacts with the main chain 222 
nitrogen of Tyr100 of LCDR3, again through a water molecule (Fig. 2B). The carboxyl 223 
group of M2-Glu14 interacts directly with the hydroxyl group of Tyr31 of LCDR1 and 224 
Tyr98 of LCDR3 through a hydrogen-bond network (Fig. 2B). The main chains of M2-Val7, 225 
-Pro10, -Arg12 and -Asn13 and the side chains of M2-Thr5, -Arg12, and -Asn13 also 226 
facilitate hydrophilic interactions with different residues in the CDRs (Fig. 2C). Finally, a 227 
hydrophobic patch formed by M2-Pro10 and -Ile11 occupies a hydrophobic pocket formed 228 
by residues Val104 of HCDR3 and Tyr31, Tyr34, Leu38, Tyr98, Tyr100 and Leu102 of 229 
LCDR1 and LCDR3 (Fig. 2D).  230 
M2-Pro10 and M2-Ile11 are essential for recognition by mAb65. Although the first 9 231 
amino acid residues of M2e are strongly conserved, starting from position 10 there is 232 
considerable variation. This is likely because this part of M2 overlaps with the C-terminal 233 
part of M1 in a +1 translational frame shift. Assuming a stronger selection pressure on M1, 234 
this implies that single nucleotide alterations at the wobble position in the M1 codons can be 235 
tolerated and result in amino acid alterations in that part of M2e. Still, we noted that M2-236 
Trp15 and to a slightly lesser extent the cysteine residues at positions 17 and 19 in M2 are 237 
nearly absolutely conserved in all available M2 sequences of influenza A viruses. To better 238 
understand the relative contribution of the M2e residues for mAb65 binding, we first 239 
performed an Ala-scan mutagenesis of M2e. For this we used M2 fused at its C-terminus 240 
with a Flag tag to allow normalization of expression levels, and cloned the corresponding 241 
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coding information in a mammalian expression vector. This Ala-scan analysis revealed that 242 
the epitope-specificity of mAb65 is similar to that of monoclonal antibody 14C2 (Fig. 2E) 243 
(38). In addition, we found that M2 amino acids Glu6, Pro10, Ile11 and Trp15 are critical for 244 
mAb65 and, to a lesser extent, also Thr5 and Glu14 (Fig. 2E). It was surprising that M2-245 
Trp15 was crucial for mAb 65 binding, because based on our crystal structure it did not 246 
make any direct contact with mAb65.  247 
Next, we immunostained cells pre-infected with different subtypes of influenza A viruses 248 
differing in their M2e sequences. MAb65 recognized M2 on the surface of cells infected 249 
with A/Puerto Rico/8/1934 virus (PR8) but bound poorly to M2 expressed by pandemic 250 
H1N1 2009, avian, and swine influenza viruses (Fig. 3A and 3B). This confirms the 251 
importance of Pro10 and Ile11 for mAb65 binding and is in line with the structural data. 252 
Indeed substitution of M2-Pro10 by His (as in Chicken/Nanchang/2001) would replace a 253 
hydrophobic residue with a polar one and reduce interactions with the hydrophobic patch at 254 
the bottom of the Fab65 paratope. In addition, the side chains of His and Leu (as in Mallard 255 
Duck/ALB/1979) would result in a steric clash, whereas an Ala residue at this position 256 
would be poorly hydrophobic. Likewise, replacement of M2-Ile11 by Thr (as in 2009 257 
pH1N1 and the avian and swine influenza viruses tested here) would replace a hydrophobic 258 
residue by a polar one, and substitution by Ala would contribute too little hydrophobicity to 259 
allow proper binding in the hydrophobic part of the Fab65 paratope. 260 
It has been reported that some influenza A virus strains display a reduced plaque size 261 
phenotype when grown in the presence of 14C2 monoclonal antibody (39). Since mAb65 262 
and 14C2 react very similar in the Ala-scan mutagenesis, suggesting a comparable epitope in 263 
M2e, we evaluated the potency of mAb65 to inhibit virus growth in a plaque assay. Growth 264 
of these four viruses (PR8, WSN, A/USSR/77 and X31) in the presence of mAb65 did not 265 
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result in less or smaller plaques, whereas amantadine and convalescent serum from infected 266 
mice, reduced plaque numbers (Fig. 3C).  267 
 We further investigated the importance of M2-Pro10 for Fab65 binding by peptide and cell 268 
ELISA. mAb65 readily bound to M2e peptide or cells expressing WT M2. Notably, 269 
substitution of M2-Pro10 to Ala or Leu strongly reduced binding of mAb65 but had only a 270 
minor effect on mAb148 (Fig. 4A and 4B). 271 
M2-Trp15 stabilizes the M2e conformation. In the Fab65 complex, M2e adopts a 272 
remarkably compact structure with a β-turn from Thr5 to Glu8 and a 310-helix from Ile11 to 273 
Trp15 (Fig. 5A). Due to the distinct U-shape, M2e-Leu4 and M2e-Gly16 are only 3.1 Å 274 
apart (Fig. 5A). This compact conformation of M2e is maintained by intra-molecular 275 
hydrophilic and hydrophobic interactions. The key residue in these intra-molecular 276 
interactions is M2e-Trp15 (Fig. 5A). Hydrophobic interactions are formed between the 277 
indole ring of M2e-Trp15 and the aliphatic parts of M2e-Glu6 and M2e-Arg12. The central 278 
position of M2e-Trp15 in M2e resembles the positioning of tryptophan in so-called Trp-279 
cages, which fold into stable mini-proteins (40). As in Trp-cages, the indole ring nitrogen of 280 
M2e-Trp15 hydrogen-bonds with the carbonyl oxygen of M2e-Thr9, and a network of other 281 
hydrogen bonds between main chain carbonyl oxygens and nitrogens of M2e confines M2e-282 
Trp15 in a central position (Fig. 5A and 5B). For such variant peptides in complex with 283 
Fab65, the predicted free energy score of M2e in which Trp15 is replaced by other amino 284 
acids strongly increases (2.39-6.48 kcal/mol). 285 
To identify structural patterns in M2e peptide in solution that could correspond to those 286 
observed in the crystal structure of the Fab65?M2e complex, we analyzed wild type M2e, 287 
M2eP10L and M2eW15G peptides by Fourier transform infrared spectroscopy (FTIR). This 288 
analysis revealed absorbance peaks and frequencies of amide I, indicating that all peptides 289 
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contain an ?-helical component (peak near 1650 cm-1, Fig. 5C). Wild type M2e and 290 
M2eW15G peptides also displayed a pronounced β-turn component (peaks from 1669 to 291 
1683 cm-1), possibly corresponding to the β-turn in the crystal structure. The FTIR spectrum 292 
of M2eP10L differed substantially from that of wild type and M2eW15G peptides, and 293 
showed characteristics of β-sheets (split peak at 1692 and 1615 cm-1, Fig. 5C) (41). The 294 
absence of a β-turn further helps to explain loss of binding of mAb65 to M2e with Pro10 295 
substitutions and was confirmed in a peptide ELISA (Fig. 4A). 296 
When Trp15 was replaced by Gly, binding of mAb65 to M2e peptide in ELISA was strongly 297 
reduced (Fig. 4A and 4B). The crucial position of Trp15 in the M2e three-dimensional 298 
structure together with its near absolute sequence conservation in influenza A viruses, 299 
including bat H17N10 and H18N11 viruses, is intriguing. At the genetic level, it is 300 
impossible to substitute any nucleotide in M2-Trp15 without altering Met244 or Gly245 in 301 
M1 (Fig. 6A). Therefore, its conservation might be imposed by a critical role of the 302 
overlapping codons in M1. Nevertheless, we introduced several substitutions for Trp15 in 303 
M2 and tried to rescue influenza A virus using an eight plasmid-based reverse genetics 304 
system for PR8 virus (32). All M2e variant viruses that we attempted to obtain would 305 
express mutant M1 except for the M2-STOP virus, in which a stop codon is introduced after 306 
M2-Asp24. Mutations M2-Trp15Ala, -Trp15Arg, -Trp15Gly and -Trp15Leu resulted in 307 
substitution of methionine at position 244 in M1 into Ser, Thr, Arg and Thr, respectively. 308 
Replacement of M2-Trp15 by Cys resulted in substitution of Gly into Arg at position 245 in 309 
M1. When we transfected the eight plasmid, we found that M1 and M2 expression levels 310 
were comparable for all mutants except M2-STOP, indicating that the introduced mutations 311 
did not affect the stability of these proteins (Fig. 6B). However, we could only rescue viruses 312 
derived from the M2-Trp15Cys and M2-STOP constructs, but the number of plaques were 313 
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very low (Fig. 6C and 6D). We tried several times to rescue virus from the plasmid 314 
combinations in which M2-Trp15 was changed into Ala, Arg, Gly or Leu (and M1 at 315 
position 244) without success. Although we cannot exclude that this result may be due to 316 
technical failure, this outcome suggests that M2-Trp15 and or M1-Met244 play an important 317 
role in virus replication. We did obtain virus from the M1-Gly245Arg/M2-Trp15Cys mutant 318 
plasmid but this virus replicated poorly as evidenced by the small plaque size and low virus 319 
titer (Fig 6C). Taken together, M2-Met244 and/or M2-Trp15 possibly play an important role 320 
in the virus life cycle. 321 
 322 
  323 
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DISCUSSION 324 
We describe the crystal structure of a prototypical M2e peptide in complex with a mouse 325 
monoclonal antibody. To our knowledge, this is the first report of a three dimensional 326 
structure of M2e. Our findings help to complete our knowledge of the atomic resolution 327 
structure of the domains of influenza A proteins that face the outside of virions and of 328 
infected cells. To determine this structure, we used a monoclonal antibody that had been 329 
isolated following immunization of BALB/c mice with M2e-tGCN4, a soluble tetrameric 330 
M2e immunogen, which we considered a good mimic of M2e in natural M2 (27). 331 
Furthermore, this monoclonal antibody protects laboratory mice against challenge with PR/8 332 
virus, and its specificity is similar to that of mAb 14C2, first described by Zebedee and 333 
Lamb (39) (Fig. 2E).  334 
We first tried to resolve the structure of M2e-tGCN4 crystals. This structure revealed that the 335 
leucine-zipper part of M2e-tGCN4 makes an angle of 15° relative to the four-fold symmetry 336 
axis (data not shown). Unfortunately, we could not accurately model the M2e part of M2e-337 
tGCN4 because the electron density map was too weak, possibly due to the high flexibility 338 
of M2e. Therefore, we decided to stabilize the M2e peptide with Fab65. An important 339 
question is the extent to which this structure resembles natural M2e as it exists in virions and 340 
on the surface of infected cells. It is likely that natural M2e is flexible and that the structure 341 
we propose here is a snapshot of one of several conformations that M2e can adopt. However, 342 
several lines of evidence support the notion that the structure of M2e in complex with Fab65 343 
does not represent merely a rare and very transient M2e conformation. First, next to binding 344 
to the M2e-tGCN4 immunogen used for the generation of Mab65, this monoclonal antibody 345 
binds with high specificity to the M2 ectodomain on the surface of infected or transfected 346 
cells and to M2 in Western blots. The binding of mAb65 to infected cells or to M2 (analyzed 347 
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by Western blot) depends on the M2e amino acids involved in the interaction between Fab65 348 
and M2e as observed in the crystal structure. Moreover, administration of low amounts of 349 
mAb65 protects mice against influenza A virus challenge. Hence, the M2e conformation we 350 
describe does occur at biologically relevant levels on the surface of infected cells. Second, 351 
the affinity (Kd = 0.4 nM), Kon (2.24 x 105 M-1.s-1) and Koff (9.2.105 x s-1) of mAb65 for 352 
M2e (Van den Hoecke et al., in preparation) are high and in the range that is known to be 353 
required for specific antibody?protein interactions (42). Finally, the well-known M2e-354 
specific mAb 14C2 generated by immunization with SDS-PAGE purified M2 binds to the 355 
same epitope as Mab65 (Fig. 2E). Together, these observations suggest that the structure of 356 
M2e in complex with Fab65 represents of that of non-complexed M2e at the surface of 357 
infected cells. 358 
MAb65 bound to M2 on the surface of cells infected with PR/8 virus but not to cells infected 359 
with influenza A viruses expressing M2 with a Pro10 and or Ile11 substitution, such as 360 
pandemic H1N1 2009 or the avian influenza viruses that we tested. The importance of these 361 
two residues for Fab65 binding was clear from the crystal structure: M2e-Pro10 and -Ile11 362 
form a hydrophobic patch that neatly fits into a hydrophobic pocket consisting of Val104 in 363 
HCDR3 and Tyr31, Tyr34, Leu38, Tyr98, Tyr100 and Leu102 in LCDR1 and LCDR 3. 364 
mAb65, like 14C2, has a LCDR1 loop 17 amino acids long. This loop completely covers the 365 
hydrophobic patch of M2e peptide (Fig. 1A). The involvement of M2e-Pro10 and -Ile11 in 366 
the interaction with the paratope is consistent with the Ala-scan results and YASARA-based 367 
predictions with FoldX plug-in (31): a Pro-to-Ala change would result in a loss of 2.16 368 
kcal/mol of interaction energy, and an Ile-to-Ala change at position 11 in a loss of 3.48 369 
kcal/mol. Generally, amino acid residues that contribute more than 2.5 kcal/mol of free 370 
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energy difference in a protein?protein interaction interface are essential for specificity and 371 
stability of the interaction (43). 372 
More than 90% of the publicly available influenza A M2 sequences have Pro10, and most of 373 
the replacements are Pro10His and Pro10Leu. In particular, many human H1N1 viruses with 374 
M2-His10 have emerged. In human influenza strains, M2-Leu10 was mainly observed 375 
among humans infected with avian influenza virus (H5N1, H9N2, and more recently H7N9). 376 
A crucial role of Pro10 for the interaction of mAbs with M2e was also apparent from a 377 
previous study showing that P10H and P10L PR/8 escape virus mutants arose in SCID mice 378 
in the presence of 14C2-like anti-M2e mAbs (26). When modeled in the structure of M2e, 379 
these mutations induce steric hindrance at the interfaces with LCDR3 and HCDR3, 380 
explaining the reduced binding and the selective advantage of escape viruses with M2-Pro10 381 
substitutions under M2e-specific mAb selection pressure. M2-Ile11 is highly conserved in 382 
human H1N1 viruses that circulated until 2009 (> 96% prevalence), but it changed to Thr11 383 
in the 2009 pandemic H1N1 virus. Substitution of M2e-Ile11 to Thr11 reduces the 384 
possibilities for hydrophobic interactions with Tyr31, Tyr34, Leu38 and Tyr98 in the L-385 
chain, and YASARA plot analysis indicated a significant energy change of 2.6 kcal/mol. 386 
This explains why the binding of mAb65 to M2 of the 2009 pandemic H1N1 is weak (Fig. 3). 387 
M2-Glu6, -Glu8, and -Glu14 are responsible for most of the hydrophilic interactions with 388 
mAb65. The side chain of M2e-Glu6 contributes four hydrophilic interactions with Fab65, 389 
either directly or via water molecules. According to YASARA, mutation of M2-Glu6 to Ala 390 
would disrupt most of these hydrogen bonded interactions and result in a predicted free 391 
energy difference of 3.44 kcal/mol at the M2e–Fab65 interface. Given the importance of 392 
M2-Glu6 for binding with Fab65, an escape virus with an M2-Glu6 substitution would most 393 
likely not be controlled by mAb65-like antibodies. However, this would imply an amino acid 394 
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substitution in M1 and M2, and as M1 is among the most conserved proteins of influenza A, 395 
such a mutation may generate an unfit virus. 396 
Recently, solid-state NMR of full-length, lipid-embedded M2 revealed that the secondary 397 
structure of M2e changed with membrane composition (44). DMPC (1,2-dimyristoyl-sn-398 
glycero-3-phosphocholine)-bound M2 exhibited a β-sheet conformation and was highly 399 
dynamic, whereas M2 bound to cholesterol-containing membranes had a predominantly α-400 
helical conformation. The N-terminal residues SLLTEVET are identical in M1 and M2, and 401 
this sequence forms an α-helix in M1 (45). FTIR analysis of M2e peptide suggests that M2e 402 
has α-helical and β-turn conformations in solution, and a β-turn is present in the M2e-Fab 403 
complex structure. The antibody recognition motif in a peptide is often a β-turn, and 404 
antigenic peptides have a tendency to adopt β-turns in solution (46-48). Additionally, peptide 405 
antigens that stabilize a β-turn have been shown to increase antibody affinity (46, 49). 406 
Having a stable conformation with a β-turn involved in antibody binding resembles that of 407 
the N-terminal peptide of HIV-1 Tat bound to a monoclonal antibody (48). We propose that 408 
natural M2e temporarily adopts a (curled) shape that is first selected and then becomes fixed 409 
upon antibody binding. Such a scenario is in line with the explanation proposed for the 410 
specificity of the interactions between ubiquitin and the many different ubiquitin-binding 411 
proteins in a cell (50). Ubiquitin-binding proteins selectively bind one particular 412 
conformation of ubiquitin from a set of many. However, the relationship between the 413 
biological function of M2e and the potential advantages of its structural adaptability remains 414 
unclear.  415 
The central position of Trp15 in the M2e structure is remarkable and resembles so-called 416 
Trp-cages, which are synthetic miniproteins that fold spontaneously into globular structures, 417 
containing a hydrophobic core and a helical segment (51). The comparison of M2e with Trp-418 
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cages suggests that M2-Pro10 might also contribute to the folding of M2 because the rigidity 419 
of proline orients the main chain oxygen of M2-Thr9 in a position that allows the formation 420 
of hydrophilic interactions with the indole ring of Trp15 (Fig. 5A and 5B)(51). Results of 421 
Ala-scan mutagenesis and ELISA indicated an important contribution of M2-Trp15 to 422 
mAb65 binding (Fig. 2E and Fig. 4A) even though this residue did not bind to the antibody. 423 
The FTIR spectrum of M2eW15G was nearly identical to that of wild type M2e, suggesting 424 
that M2-Trp15 controls the tertiary structure but not the secondary structure of M2e (Fig. 425 
5C). M2-Trp15 is extremely conserved: only eight mutations occur at this position in over 426 
28,000 M2 sequence entries in the NCBI databank. M42, which has a different M2e 427 
sequence, could functionally replace M2 (52). Even in this case, as well as in the predicted 428 
M2 proteins of the H17N10 and H18N11 influenza viruses, M2-Trp15 is conserved (53). We 429 
could not rescue M1-Met244/M2-Trp15 mutant viruses. It is possible that failure to rescue 430 
these viruses was due to a possible role for M2-Trp15 in the ion channel activity of M2. 431 
However, we found that transfection of HEK293T cells with wild type or M2-Trp15 mutant 432 
expression vectors, was equally cytotoxic and resulted in a comparable increase in the 433 
luminal pH of the Golgi (unpublished results). M2-Trp15 mutant viruses inevitably have M1 434 
mutations, and it cannot be ruled out that the reason for the very high sequence conservation 435 
of M2-Trp15 is driven by the functional conservation of Arg243, Met244, and Gly245 of M1. 436 
Although the part of M1 following Ala200 does not affect binding to vRNPs (54), it is 437 
involved in determining the morphology of influenza A virus (55).  438 
Anti-M2e antibodies generally inhibit viruses not by direct neutralization but by antibody-439 
dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis 440 
(17). This is partly related to the small number of M2 proteins that are incorporated in 441 
virions (20 to 60 molecules/virion) despite the abundance of M2 on the infected cell surface 442 
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(1, 39). Grandea et al. reported that human monoclonal antibodies TCN-031 and TCN-032 443 
bind to influenza A virions (19). These two antibodies bind to the N-terminal end (Ser2 to 444 
Glu6). Fu et al. reported that oligomerization of M2e improves the affinity of M2e-specific 445 
antibodies and protection of mice against lethal influenza virus challenge (56). Therefore, 446 
despite its small size, it is likely that M2e is dynamic and displays various conformations 447 
that can be targeted by different antibodies with different affinities.  448 
In summary, our study reveals, for the first time, a snapshot of the structure of M2e. We 449 
propose that M2e has different conformations, including a curled structure that can induce 450 
high affinity M2e-specific antibodies. The structure of M2e in complex with a protective 451 
antibody may guide the design of an M2e vaccine with a stabilized conformation. According 452 
to the structure described here, mutation of Pro10-to-His or Ile11-to-Thr will abolish binding. 453 
This implies that circulating influenza viruses with M2-His10 or -Thr11 would not be bound 454 
by mAb65-like antibodies. However, active vaccination strategies induce an oligoclonal 455 
response to M2e, and some human monoclonal antibodies recognize the N-terminal part of 456 
M2e, suggesting that M2e remains a universal influenza A vaccine candidate. 457 
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FIGURE LEGENDS 671 
 672 
FIG 1 Structure of M2e in complex with Fab65. (A) Left: Overall structure of the M2e 673 
(magenta) and Fab65 (green for light chain and blue for heavy chain) complex. Upper right: 674 
LCDR1 (dark green) flanks M2e (magenta), contacting the 310-helix. Lower right: Top view 675 
with cartoon presentation of M2e (magenta) in complex with the heavy chain (marine) and 676 
light chain (green) of Fab65. (B) Surface representation of M2e bound to Fab65 viewed from 677 
the paratope towards M2e. M2e is color-coded according to the electrostatic potential. Color 678 
scale was set from ?10 kT/e (red) to 10 kT/e (blue), as calculated by the APBS tool plugged 679 
in Pymol. LCDR and HCDR residues that interact with M2e are shown in stick presentation 680 
in green and marine, respectively. (C) Comparison of shape complementarity scores of 681 
different antibody-epitope complexes. Black bars represent shape complementarity (SC) 682 
scores deduced from co-crystalized influenza hemagglutinin HA and Fab fragments 683 
deposited in the PDB database. The red bar on the right indicates the SC of M2e/Fab65 684 
(4N8C). 685 
FIG 2 Details of the main interactions between M2e and Fab65. (A) Close-up view of 686 
hydrophilic interactions between M2e-Glu6 and Fab65. Dotted lines represent hydrogen 687 
bonds and salt bridges. (B) Water mediated interactions and (C) other hydrophilic 688 
interactions between M2e amino acid residues (colored in purple) and Fab65 amino acid 689 
residues (light chain colored in green and heavy chain colored in blue). (D) Hydrophobic 690 
interactions between M2e and mAb65 with surface presentation of Fab65 (left) and M2e 691 
(right) color-coded according to the electrostatic potential. Colour scale was set from ?10 692 
kT/e (red) to 10 kT/e (blue), as calculated by the APBS tool plugged in Pymol. (E) 693 
Reactivity of mAb65 and 14C2 with M2 was analyzed by western blot of lysates of HEK-694 
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293T cells transfected with M2-Flag expression constructs carrying M2e-Ala mutants. Anti-695 
Flag detection was used to normalize the amount of M2 in the cell lysates that were loaded. 696 
NC = negative control. 697 
FIG 3 Binding of mAb65 to cells infected with influenza A virus. (A) Confocal images of 698 
immunofluorescence staining of MDCK cells infected with influenza virus. M2-staining is 699 
shown in red fluorescence and was revealed using mAb65 or mAb148 (TCN-031 like 700 
antibody, binds to the N-terminus of M2). Goat polyclonal antibody against influenza virus 701 
ribonucleoprotein (BEI Resources NR-3133) was used to stain viral RNPs (green). Cell 702 
nuclei were identified by DAPI staining (blue). (B) Amino acid sequence alignment of M2e 703 
from different influenza A viruses. The conserved Trp15 is highlighted in bold. (C) mAb65 704 
does not affect influenza A virus plaque size. PR8, WSN, A/USSR/77 and X31 viruses were 705 
used in a plaque assay on MDCK cells in the presence of antibodies, amantadine or immune 706 
sera with virus neutralizing activity. The plaque assay was performed in a 96-well format 707 
and the plaques were visualised by immune-staining with goat anti-vRNP immune serum. 708 
mAb65, mAb148 and mAb3G8 (isotype matched negative control mAb) were used at a 709 
starting concentration of 10 μg/ml. Amantadine was used at a starting concentration of 100 710 
μM. anti-HA means goat antiserum against PR8 virus (BEI Resources NR-3148) with strong 711 
neutralizing activity against PR8 and WSN viruses and some neutralizing activity against 712 
A/USSR/77 and X31 viruses. “Virus dilution” means serial tenfold dilution of the amount of 713 
virus that was used to inoculate the cells in the presence of mAb, amantadine or anti-HA 714 
serum, which were used as tenfold serial dilutions as indicated at the top.  715 
FIG 4 Binding properties of mAb65 to M2e peptide and M2-expressing cells. (A) Binding 716 
of mAb65 and mAb148 to different M2e peptides. ELISA plates were coated with wild type 717 
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(WT), M2eW15G or M2eP10L M2e peptides at 20 ng/ml or 200 ng/ml as indicated. (B) 718 
Cellular ELISA using HEK-293T cells that had been transfected with wild type, 719 
M2Trp15Ala, or M2Pro10Ala M2-Flag expression vectors.  720 
FIG 5 Structure of M2e. (A) Top: M2eTrp15 occupies a central position in M2e. The 721 
distance between the main chain oxygen of M2eLeu4 and the nitrogen of M2eGly16 is 3.1 Å 722 
(double arrow). Bottom: The β-turn involving Thr5 to Glu8 in M2e (left) and a 310-helix 723 
from Ile11 to Trp15 (right). Dotted lines represent hydrophilic interactions. (B) The position 724 
and interactions of M2eTrp15 in M2e (top) resemble those of Trp in a Trp-cage miniprotein 725 
(bottom). (C) Fourier transform infrared spectroscopy spectra of M2e peptides. Each 726 
spectrum was normalized and subtracted from the spectrum of the PBS buffer. Shown are 727 
FTIR spectra of wild-type M2e peptide (red), M2eW15G (blue) and M2eP10L (purple). The 728 
data shown are the average of 256 recorded spectra with a resolution of 2 nm.  729 
FIG 6 Recombinant PR/8 virus with M2-Trp15 substitution is highly attenuated. Wild type 730 
PR/8 and PR/8 with M2 mutations that alter M2-Trp15 were generated by introducing the 731 
corresponding mutations in a plasmid-based reverse genetics system. Sets of eight plasmids 732 
were transfected into HEK293T-MDCK co-cultures to determine the expression of viral 733 
proteins and to try to rescue the virus. (A) Schematic representation of the codon usage and 734 
amino acid sequence near M2-Trp15 in M1 and M2 wild type and mutant PR/8 viruses (B) 735 
Western blot analysis of cell lysates prepared 24 h after transfection to evaluate expression 736 
of NP, M2 (revealed by staining with mAb148 and mAb65) and M1, as indicated. WT (wild 737 
type), NC (negative control, i.e. transfected with only pCAXL-PA, pCAXL-PB1, pCAXL-738 
PB2, and pCAXL-NP), ST (Stop: mutant with stop codons introduced after M2-Asp24), NT 739 
(non-transfected). (C) Plaque assay to quantify rescued PR/8 viruses with introduced 740 
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M1/M2Trp15 mutations. (D) Hemagglutinating activity in the supernatant of transfected 741 
HEK293T-MDCK co-cultures. The supernatant and serial three-fold dilutions were assayed 742 
for hemagglutination of chicken red blood cells on day 2 or 5 after transfection with the 743 
eight-plasmid system used for generating PR/8 virus. 744 
  745 
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TABLE 1 Crystallographic X-ray diffraction and refinement statistics  746 
Data statistics M2e peptide + Fab65 
Wavelength (Å) 0.980 
Number of reflections  
(unique reflections) 429,800 (109,543) 
Resolution range (Å) 50.0~1.60 (1.66~1.60) 
Completeness (%) 96.9 (95.2) 
Rmerge (%)a 5.4 (67.4) 
I/sigma 24.2 (1.8) 
Space group P1 
Unit cell parameters (Å) a=40.4, b=72.3, c=78.4 
 α=86.9 o, β=77.5o, γ=84.6o 
Refinement statistics  
Resolution range (Å) 38.4~1.6 
Number of reflections 104,049 
R/Rfree (%)b 19.3/24.3 
r.m.s. deviation  
   bonds (Å) 0.019 
   angles (°) 1.96 
# of water molecules 691 
Average B (Å2) 26.8 
Ramachandran statistics (%)c  
Favored 97.5 
Allowed 2.2 
Outlier 0.1 
aRmerge = ?|I - <I>|/?<I>, where I and <I> are the measured and averaged intensities of 747 
multiple measurements of the same reflection, respectively. The summation is over all the 748 
observed reflections. 749 
bR = Σ|Fo – Fc|/Σ|Fo| calculated for all observed data. Rfree = Σ|Fo – Fc|/Σ|Fo| calculated for a 750 
specified number of randomly chosen reflections that were excluded from the refinement. 751 
cCalculated using RAMPAGE (57). 752 




















